---
title: "Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294056102.md"
description: "Altimmune reported positive Phase 2 RECLAIM topline results for pemvidutide 2.4 mg in AUD. The drug significantly reduced heavy drinking days versus placebo, meeting primary and two FDA-recognized secondary endpoints. It also showed significant improvements in biomarkers (PEth) and abstinence rates with generally favorable tolerability, though GI adverse events were noted. Altimmune plans to request an End-of-Phase 2 meeting with the FDA."
datetime: "2026-07-28T11:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294056102.md)
  - [en](https://longbridge.com/en/news/294056102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294056102.md)
---

# Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD

**Altimmune announced positive topline Phase 2 results for pemvidutide 2.4 mg showing a significant reduction in heavy drinking days versus placebo.**

**Key Highlights:**

-   RECLAIM met its primary endpoint: pemvidutide reduced heavy drinking days/week vs placebo by 1.45 days (p=0.0014).
-   Two FDA-recognized registrational secondary endpoints met: 2-level WHO risk reduction (64.4% vs 34.8%, p=0.0049) and zero HDD (42.2% vs 17.4%, p=0.0066).
-   Significant biomarker and abstinence effects: PEth reduced (LS mean diff -175.3, p<0.0001); percent days abstinent up 18.4% (p=0.0075).
-   Generally favorable tolerability; more GI AEs with pemvidutide (nausea 44%, vomiting 18%) and 10% had drug-related discontinuations.
-   Company plans to request an End-of-Phase 2 meeting with the FDA and will submit data for conference presentation and publication.

Original SEC Filing: Altimmune, Inc. \[ ALT \] - 8-K - Jul. 28, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

- [Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial](https://longbridge.com/en/news/294079208.md)
- [ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinence](https://longbridge.com/en/news/294057380.md)
- [Altimmune's drug meets main goal of mid-stage study for alcohol use disorder](https://longbridge.com/en/news/294056614.md)
- [Abivax says FDA pre-NDA feedback supports planned obefazimod filing by end-2026](https://longbridge.com/en/news/294409492.md)
- [Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near](https://longbridge.com/en/news/289332663.md)